MannKind Corporation

MannKind is excited to announce that the U.S. Food and Drug Administration (FDA) has approved the first needle-free treatment option for pediatric patients living with type 1 diabetes. Learn more in the Company Announcement here: https://bit.ly/4tYQgqV Important Safety Information: https://bit.ly/4tYQgqV Prescribing Information: https://bit.ly/4dBCEwL #Press #FDA #Diabetes #T1D

MannKind is gearing up for the American Diabetes Association (ADA) 2026 Scientific Sessions June 5-8 in New Orleans! Stop by the MannKind booth (#909) to learn the latest updates with inhaled insulin and recharge with a coffee at our Breathe Café. While you’re there, don’t miss our immersive virtual reality experience that allows you to ride a Technosphere® particle from the inhaler into the human body. We’re also proud to share nine poster presentations at #ADA2026, including new data advancing the understanding of inhaled insulin in pediatric care, pregnancy, and use alongside automated insulin delivery (AID) systems—be sure to check out the graphic below for more details! 

MannKind was proud to be recognized as the 2026 honoree at the Breakthrough T1D CT & Western MA Gala, an evening uniting the type one diabetes community in support of a cure. We’re honored to support Breakthrough T1D’s mission and proud to stand alongside a community committed to improving the lives of those living with diabetes and driving toward a cure.

MannKind is honored to be named to TIME Magazine’s World’s Most Impactful Companies 2026 list—a select group of organizations driving meaningful change through their core business activities. At MannKind, this aligns directly with our commitment to delivering innovative, patient-centric solutions that help people live life more freely. This recognition is made possible by our Mannitarians whose passion and daily dedication bring our mission to life. By pushing boundaries and doing right, they make this impact possible.

MannKind was honored to host diabetes advocates from across Southern California for thoughtful discussions on the realities, challenges, and future of diabetes care. Centered on real world experiences, these conversations help guide how we continue to strengthen our support for the diabetes community. #PatientAdvocacy

MannKind is attending the ATS Respiratory Innovation Summit 2026 in Orlando, which unites leaders across the field advancing powerful new treatments for deadly and crippling diseases of the lungs and airways. Join us on Saturday, May 16 at 11:30 a.m. ET for MannKind’s Showcase presentation by Wassim Fares, MD, MSc to learn more about nintedanib DPI which is currently being evaluated for IPF. We also invite you to visit us at Booth #2436 during the #ATS2026 International Conference, taking place May 15–20.

MannKind has released its Q1 2026 financial results.  Click here to watch the webcast replay: https://bit.ly/4uyLlxx

On #SchoolNurseDay, we celebrate school nurses for the critical role they play in supporting student health and academic success nationwide. At MannKind, we’re grateful for their commitment to helping students, including those living with diabetes, feel supported every day. #SND2026

MannKind announced that its previously disclosed MNKD-1501 collaboration with United Therapeutics is a ralinepag dry powder formulation that is being developed for pulmonary hypertension and fibrotic lung diseases. MannKind is eligible to receive up to $35 million in development milestones plus 10% royalties on net sales. Read the full press release here: https://bit.ly/49awkdU

At MannKind, we know kids with diabetes are defined by so much more than their diagnosis. That’s why we’re launching More Than Type 1, a space filled with real tips, real stories, and real advice from kids and caregivers who truly understand life with type 1 diabetes. When daily diabetes management becomes simpler, there’s more room for everything else. Click here to visit the More Than Type 1 website: https://bit.ly/4sMXMEA